Provided by Tiger Trade Technology Pte. Ltd.

Natera

408.47
-4.8400-1.17%
Post-market: 408.470.00000.00%19:30 EDT
Volume:1.86M
Turnover:772.56M
Market Cap:58.50B
PE:-297.52
High:423.43
Open:413.31
Low:407.37
Close:413.31
52wk High:427.47
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.02
T/O Rate:1.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:32.12
PE(LYR):-267.52

Loading ...

Natera price target raised to $475 from $360 at Guggenheim

TIPRANKS
·
Yesterday

Movement Alert|Natera Rises 3.05% in Regular Trading, RBC Raises Target Price to $460 Citing Signatera Genome Dominance Potential

Market Focus
·
Sep 30

Natera (NTRA) Receives a Buy from Bernstein

TIPRANKS
·
Sep 26

Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says

MT Newswires Live
·
Sep 25

RBC Raises Price Target on Natera to $460 From $350, Keeps Outperform Rating

MT Newswires Live
·
Sep 25

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Natera, Inc. : RBC Raises Target Price to $460 from $350

THOMSON REUTERS
·
Sep 25

Movement Alert|Natera Rises 3.22% in Regular Trading, Signatera Approved in Japan for Bladder Cancer Companion Diagnostic as Multiple Banks Raise Price Targets

Market Focus
·
Sep 24

Natera Inc Stock (NTRA) Moved Up by 5.67% on Sep 22: Facts Behind the Movement

TradingKey
·
Sep 23

Movement Alert|Natera Rises 3.1% in Regular Trading, Signatera Test Approved in Japan as Bladder Cancer Companion Diagnostic

Market Focus
·
Sep 22

Natera’s Signatera Wins Japan PMDA Approval as Companion Diagnostic in Muscle-Invasive Bladder Cancer

Reuters
·
Sep 22

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

THOMSON REUTERS
·
Sep 22

Natera- Signatera Commercial Launch in Japan Expected in 1H 2027

THOMSON REUTERS
·
Sep 22

Natera Says Lung Cancer MRD Study Links Signatera Results to 3-Year Recurrence-Free Survival in 1,129 Patients

Reuters
·
Sep 18

Natera Inc Stock (NTRA) Moved Up by 5.05% on Sep 17: Key Drivers Unveiled

TradingKey
·
Sep 18

Movement Alert|Natera Rises 3.18% in Regular Trading, Multiple Investment Banks Significantly Raise Price Targets

Market Focus
·
Sep 17

Natera Executive Chairman Matthew Rabinowitz Disposes of 89,100 Common Shares Worth $30.15 Million

Reuters
·
Sep 17

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Centene (CNC), Natera (NTRA) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Sep 15

Natera Executive Chairman Matthew Rabinowitz Disposes of USD 16.32 Million in Common Shares

Reuters
·
Sep 12